Oncolytic Immunotherapy Using Chimeric HSV C134: A Phase I Trial and Establishment of Response Indicators in Recurrent Glioma Patients

Grant

Date/time Interval

  • September 18, 2018 - August 31, 2021

    • Awarded By

    Total Award Amount

  • 1680234.00

    • Direct Costs

  • 1361656.00

    • Sponsor Award Id

  • R01CA222903

    • Contributor

  • C. Ryan Miller   Investigator  
  • Caitlin Dalgo MSN, BSN, RN   Investigator  
  • Gary Cutter   Investigator  
  • George Gillespie   Investigator  
  • Inmaculada Aban   Investigator  
  • James Markert M.D., M.P.H.   Principal Investigator  
  • Jianmei Leavenworth Ph.D.   Investigator  
  • Louis Nabors M.D.   Investigator  
  • Mina Lobbous   Investigator